SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
Abraxane and Gemcitabine Improves Overall Survival
Study Uncovers New Mechanism In Class of Chemotherapy Drugs
Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
Genetic Test Identifies Patients With High Risk of Mortality
Memantine Can Delay Onset Of Cognitive Function Decline
Doxepin Rinse Reduces Pain In Radiation Therapy Patients
Zaltrap Receives Positive Opinion For European Market From CHMP
NCI-Approved CTEP Trials For the Month of November
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- Long-term risks from prostate cancer treatment detailed in new report
- FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients
